Transactions -- ANS / Publications / Transactions

About ANS
- ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
About Nuclear
- Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Communities
- Division Spotlight
  Education, Training & Workforce Development
  The Education, Training & Workforce Development Division provides communication among the academic, industrial, and governmental communities through the exchange of views and information on matters related to education, training and workforce development in nuclear and radiological science, engineering, and technology. Industry leaders, education and training professionals, and interested students work together through Society-sponsored meetings and publications, to enrich their professional development, to educate the general public, and to advance nuclear and radiological science and engineering.
Events
- Meeting Spotlight
  Nuclear Energy Conference & Expo (NECX)
  September 8–11, 2025
  Atlanta, GA|Atlanta Marriott Marquis
Standards
- Standards Program
  The Standards Committee is responsible for the development and maintenance of voluntary consensus standards that address the design, analysis, and operation of components, systems, and facilities related to the application of nuclear science and technology. Find out What’s New, check out the Standards Store, or Get Involved today!
Publications
- Latest Magazine Issues
  Jun 2025
  Jan 2025
  Latest Journal Issues
  Nuclear Science and Engineering
  August 2025
  Nuclear Technology
  August 2025
  Fusion Science and Technology
  July 2025
- Latest News
  Orano Med expands its Texas Pb-212 R&D center
  Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated the expansion of its main research and development center located in Plano, Texas. The facility is used in the development of radiopharmaceuticals and for conducting preclinical research focused on targeted alpha therapies using lead-212, an alpha-emitting radioisotope that has shown promise in treating various types of cancer.
Search